Trajentinduo Tablet 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daehwa Pharmaceutical Co., Ltd.
MFDS item code 201907009 · Approved 2019.10.01
This product's status changed to Expired on 2024.10.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling their blood sugar. It contains both linagliptin and metformin, making it particularly suitable for those who are combining dietary and exercise therapies. This helps in managing blood glucose levels more effectively. Improved blood sugar control can also have positive effects on the prevention of complications. Thus, this medication is useful for improving blood sugar management in patients with type 2 diabetes.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience with antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is one tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to one tablet of this medicine 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant treatment with linagliptin and metformin: Patients switching from concomitant treatment with linagliptin and metformin to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with concomitant metformin and sulfonylurea: The initial dose should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see section 2, Patients Requiring Cautious Administration, under Precautions for Use). 5. Patients unable to achieve adequate glycemic control with concomitant insulin and metformin: The initial dose should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see section 2, Patients Requiring Cautious Administration, under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 1, Patients Who Must Not Take This Medicine, under Precautions for Use).
This medication can potentially cause a serious side effect known as lactic acidosis and should not be administered to patients, particularly those with impaired renal function, or those with poor heart or liver function. Patients with allergies to the ingredients of this medication, those with type 1 diabetes, patients with acute myocardial infarction, and pregnant or breastfeeding women should also avoid using it. Caution should be exercised when using with medications that pose a risk of hypoglycemia, and blood glucose should be monitored closely. Adjustments to the dosages of such medications may be necessary. Symptoms of lactic acidosis include muscle cramps, abdominal pain, and severe fatigue; if these symptoms occur, consult a doctor immediately. In situations where renal function may vary, the use of this medication should be temporarily halted, and renal function should be reassessed, with regular kidney function tests being of utmost importance. Discontinuing this medication may be necessary around acute illness or pre-and post-surgery; it should only be resumed once renal function has returned to normal after surgery. This medication may induce rare skin diseases such as pancreatitis or bullous pemphigoid, so if sudden severe abdominal pain or skin blisters occur, medical personnel should be notified immediately. Long-term use may lead to vitamin B12 deficiency; if anemia or neurological symptoms are observed, vitamin B12 levels should be checked and supplementation provided if necessary. This medication can interact with other drugs, so patients must inform healthcare providers of all medications they are taking, especially if those medications may affect renal function. Pregnant women or those planning to become pregnant should not use this medication and should consider insulin therapy for blood sugar control. Breastfeeding women should also avoid using this medication and should consult about alternatives. It is advisable to avoid using this medication in children under 10 years of age, as safety and efficacy have not been established. Elderly patients are at a higher risk for declining renal function, so regular assessments of kidney function and dosage adjustments should be made when using this medication. In case of overdose, the risk of lactic acidosis increases; if symptoms arise, seek medical treatment immediately, and procedures such as dialysis may be necessary. This medication should be stored out of reach of children, protected from moisture, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture; therefore, the container must be tightly sealed for storage. A storage temperature of 1 to 30 degrees Celsius should be maintained. Proper storage will help maintain the effectiveness of the medication for a prolonged period.
Light pink, double convex oval film-coated tablet
30 tablets/box [6 tablets/PTP x 5]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daehwa Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.